At the Fintech Day & Awards 2025, industry experts discussed AI's evolving role in financial services, highlighting current limitations and potential for future automation while emphasizing the continued importance of human oversight.

XOMA Royalty and LAVA Therapeutics amended their share purchase agreement, reducing the initial cash amount per share to $1.04 and introducing a contingent value right (CVR). The tender offer has been extended to November 12, 2025, with the acquisition expected to close in Q4 2025.

XOMA Royalty has extended its tender offer to purchase all outstanding shares of LAVA Therapeutics until October 17, 2025, with a cash payment and a contingent value right per share. The proposed acquisition is expected to close in Q4 2025, subject to customary closing conditions.

XOMA Royalty Corporation has extended its tender offer to purchase LAVA Therapeutics shares until October 17, 2025, with a cash payment and contingent value right per share. The proposed acquisition is expected to close in Q4 2025, subject to customary closing conditions.

XOMA Royalty Corporation announced a definitive agreement to acquire LAVA Therapeutics for $1.16-$1.24 per share in cash, plus a contingent value right, with the transaction expected to close in Q4 2025.